Plain-English translation of NCT07645690 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing ET-970, an experimental therapy made from immune cells that are designed to recognize and attack kidney cancer cells. The medication is given as a single infusion into the bloodstream. Researchers want to understand whether this treatment is safe and whether it can help people whose kidney cancer has progressed despite previous treatments.
Kidney cancer often comes back or spreads after standard treatments like immunotherapy and targeted drugs. This trial exists because doctors need new options for patients whose cancer is no longer responding to available treatments, and this medication represents a promising new approach using the body's own immune system.
You likely qualify if…
You likely don't qualify if…
You will receive one infusion of the medication into your vein during the treatment period. Your participation lasts approximately 57 weeks (about 13 months) from the time you sign consent. During this time, you will attend clinic visits for blood tests, imaging scans, heart and lung function checks, and follow-up assessments to monitor how well the treatment works and to watch for any side effects.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
China